EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Treating, Masking, or Mismeasuring? A Measurement-First Reframing of GLP-1 Receptor Agonists Across the Eating-Disorder Spectrum

Maja Sosnowska, Leszek Czupryniak

Endocrines · 20.08.2026 · 7 (3) · 48

DOI: 10.3390/endocrines7030048 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Endocrines, online erschienen am 20.08.2026. Verfasst von Maja Sosnowska und 1 weiteren Autor:innen. Die Arbeit nennt 45 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and the dual GIP/GLP-1 co-agonist tirzepatide are increasingly prescribed for obesity and type 2 diabetes in populations enriched for binge-spectrum eating pathology. A recurring controversy asks whether these agents treat eating pathology or merely mask it. This critical narrative review argues that, posed as a simple binary, the question is under-specified, and reframes it around three problems. The central is a measurement problem: several intended effects of GLP-1 RAs are scored as improvement by eating-disorder instruments, creating a diagnostic blind spot. In the one disorder where a weight-acting drug has been tested against a placebo, efficacy on weight coincided with no effect on the psychological core—the dissociation that confounds measurement during GLP-1 RA therapy. The second is a phenotype problem: because BED subtypes already moderate response to drug versus psychological treatment, an agent acting on appetite and reward should not act uniformly, though this remains a hypothesis. The third concerns the post-discontinuation trajectory, and a therapy–harm asymmetry emerges across the spectrum. A factorial, phenotype-stratified trial with disorder-core endpoints and drug-free follow-up could resolve these questions; meanwhile, prudent practice combines uncontaminated pre-treatment screening, monitoring not reliant on confounded self-report, discontinuation planning, and integration with psychological care.

Zitieren

APA

Sosnowska, M., & Czupryniak, L. (2026). Treating, Masking, or Mismeasuring? A Measurement-First Reframing of GLP-1 Receptor Agonists Across the Eating-Disorder Spectrum. Endocrines, 7(3), 48. https://doi.org/10.3390/endocrines7030048

Vancouver

Sosnowska M, Czupryniak L. Treating, Masking, or Mismeasuring? A Measurement-First Reframing of GLP-1 Receptor Agonists Across the Eating-Disorder Spectrum. Endocrines. 2026;7(3):48. doi:10.3390/endocrines7030048

BibTeX
@article{Sosnowska2026,
  author = {Sosnowska, Maja and Czupryniak, Leszek},
  title = {Treating, Masking, or Mismeasuring? A Measurement-First Reframing of GLP-1 Receptor Agonists Across the Eating-Disorder Spectrum},
  journal = {Endocrines},
  year = {2026},
  volume = {7},
  number = {3},
  pages = {48},
  doi = {10.3390/endocrines7030048}
}
Kostenlos starten →